German companies active in the healthcare sector demonstrate a strong economic footprint in Greece, generating a combined annual turnover of 1.7 billion euros across the pharmaceutical market and medical technology (MedTech), and employing approximately 1,800 people.
According to data from the Health Committee of the German-Hellenic Chamber of Commerce and Industry, German pharmaceutical companies account for annual revenues of around 1.5 billion and employ over 1,300 people. In the MedTech sector, they employ more than 500 people, generate total annual revenues exceeding 200 million, and hold a market share of 30%.
With a presence in Greece spanning more than a century, German healthcare companies have steadily strengthened both their financial performance and their overall market position, securing leading roles in areas such as assisted reproduction (IVF), diabetes, oncology, rare diseases, cardiovascular conditions, and home-based care management (including oxygen therapy, sleep apnea, and ALS). They distribute and manufacture both historically significant and newly developed innovative medicines.
The innovation footprint of German healthcare companies is particularly strong, with one in ten innovative medicines (excluding hospital-only drugs) originating from these firms. Their contribution to clinical research is equally notable: more than 100 clinical trials involving innovative medicines have been conducted in Greece over the past five years. “Healthcare companies that are members of the German-Hellenic Chamber of Commerce and Industry actively support the broader effort for Greece to become a model country in Europe in terms of fostering healthcare innovation and strengthening Europe’s strategic autonomy in this field,” stated Manolis Mitakis, Chairman of the Chamber’s Health Committee. With regard to the “Medical Technology” (MedTech) segment, German companies hold leading positions in medical imaging, endoscopy, digital health solutions, and laboratory diagnostics.
They have also been pioneers in operating room digitalization (first introduced in Greece in 2004), as well as in innovations such as exoscopy, fluorescence imaging, and endoscopy-assisted difficult intubation. “The contribution of the Chamber’s healthcare member companies to sustainable development is equally significant, ranging from exports of innovative pharmaceuticals to corporate social responsibility initiatives and environmental protection,” Mitakis added. Referring to the Committee’s vision, he noted that it focuses on “improving population health through access to innovation, contributing to a sustainable and efficient healthcare system, and strengthening clinical research while leveraging production and export capabilities.”
According to Mitakis, “the Health Committee supports the public sector in the digital transformation of healthcare—from prevention to treatment—and promotes system efficiency through innovative MedTech solutions, with a particular focus on patient twinning, healthcare AI, and personalized medical technology.”
Για να εμφανίζονται περισσότερα άρθρα της Ναυτεμπορικής στις αναζητήσεις σας εύκολα και γρήγορα, πρέπει να προσθέσετε το site στις προτιμώμενες πηγές σας. Μπορείτε να το κάνετε πηγαίνοντας εδώ.
